Joel Sebastian Temme

Title: Joel Sebastian Temme: Innovator in HIV Research

Introduction

Joel Sebastian Temme is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of biomedical research, particularly in the development of oligonucleotides that target HIV.

Latest Patents

Temme holds a patent for "Glycosylated oligonucleotides that mimic the HIV-1 epitope of neutralizing monoclonal antibody 2G12." This patent discloses oligonucleotides that bind specifically to the HIV neutralizing monoclonal antibody 2G12 with a K value lower than 20 nM. The oligonucleotide comprises a predicted structure at 37°C, featuring exactly one stem-loop. The loop includes the nucleotide sequence AACCACGGAAAA (SEQ ID NO: 1), where one of the nucleotides in the stem includes a modified nucleoside base. The modified nucleoside base has the structure -B-L-A, where A is a branched-chain Manoligosaccharide, L is a linker molecule, and B is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide. The patent also covers immunogenic conjugates and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate, along with various methods of using these innovations.

Career Highlights

Temme is affiliated with Brandeis University, where he continues to engage in groundbreaking research. His work focuses on the intersection of molecular biology and immunology, contributing to advancements in therapeutic strategies against HIV.

Collaborations

Temme has collaborated with Isaac Jonathan Krauss, further enhancing the scope and impact of his research endeavors.

Conclusion

Joel Sebastian Temme is a prominent figure in the field of HIV research, with a patented innovation that holds promise for future therapeutic applications. His contributions continue to shape the landscape of biomedical research.